Education
About Us
Working with TipRanks
Follow Us
Biote Corp. (BTMD)
:BTMD
BTMD Stock Chart & Stats
$2.58
-$0.14(-2.36%)
At close: 4:00 PM EST
$2.58
-$0.14(-2.36%)
Day’s Range― - ―
52-Week Range$2.43 - $6.98
Previous CloseN/A
Volume19.10K
Average Volume (3M)122.81K
Market Cap
$117.81M
Enterprise Value$236.23M
Total Cash (Recent Filing)$28.05M
Total Debt (Recent Filing)$106.41M
Price to Earnings (P/E)3.1
Beta0.96
Next Earnings
Mar 18, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.22
Shares Outstanding32,268,460
10 Day Avg. Volume157,514
30 Day Avg. Volume122,806
Financial Highlights & Ratios
PEG Ratio-2.30
Price to Book (P/B)-2.00
Price to Sales (P/S)1.07
P/FCF Ratio5.46
Enterprise Value/Market Cap2.01
Enterprise Value/Revenue1.21
Enterprise Value/Gross Profit1.67
Enterprise Value/Ebitda5.10
Forecast
1Y Price Target
$3.67Price Target Upside42.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.58
Revenue Forecast (FY)$192.73M
Bulls Say, Bears Say
Bulls Say
EarningsEBITDA beat by +12% on gross margins and FY25 guide was reiterated.
Management StrategyChanges implemented to improve the sales force productivity and a renewed focus on driving sustainable growth.
ValuationValuation remains inexpensive at ~4x FY2 EV/EBITDA.
Bears Say
Clinic GrowthProcedure revenue declined by -8.4% reflecting lower new clinic growth, higher than normal attrition of established clinics, and lower procedure volume.
Full Year GuidanceOngoing disruptions weighed on Procedure revenue and management revised down full year guidance.
Revenue OutlookManagement lowered both revenue and EBITDA outlook and now expects revenue above $190mm vs. $202-$208mm prior and adj. EBITDA above $50mm vs. $59-$64mm prior.
biote News
BTMD FAQ
What was Biote Corp.’s price range in the past 12 months?
Biote Corp. lowest stock price was $2.43 and its highest was $6.98 in the past 12 months.
What is Biote Corp.’s market cap?
Biote Corp.’s market cap is $117.81M.
When is Biote Corp.’s upcoming earnings report date?
Biote Corp.’s upcoming earnings report date is Mar 18, 2026 which is in 119 days.
How were Biote Corp.’s earnings last quarter?
Biote Corp. released its earnings results on Nov 05, 2025. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.078 by $0.142.
Is Biote Corp. overvalued?
According to Wall Street analysts Biote Corp.’s price is currently Undervalued.
Does Biote Corp. pay dividends?
Biote Corp. does not currently pay dividends.
What is Biote Corp.’s EPS estimate?
Biote Corp.’s EPS estimate is 0.04.
How many shares outstanding does Biote Corp. have?
Biote Corp. has 32,268,460 shares outstanding.
What happened to Biote Corp.’s price movement after its last earnings report?
Biote Corp. reported an EPS of $0.22 in its last earnings report, beating expectations of $0.078. Following the earnings report the stock price went down -3.072%.
Which hedge fund is a major shareholder of Biote Corp.?
Currently, no hedge funds are holding shares in BTMD
biote Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.67 (42.25% Upside)
$3.67 (42.25% Upside)
Blogger Sentiment
Bullish
BTMD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 152.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.95%
Trailing 12-Months
Company Description
Biote Corp.
biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.
BTMD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Biote faced challenges with declining procedure revenue and adjusted EBITDA, largely due to the ongoing transformation of its commercial team and higher attrition rates. However, the company showed positive signs with growth in dietary supplements, improved gross profit margin, increased cash flow, and strategic share repurchases. The successful marketing event also reinforced its market leadership.View all BTMD earnings summariesBTMD Stock 12 Month Forecast
Average Price Target
$3.67
▲(42.25% Upside)
Technical Analysis
Concord Medical Services
―
Joint
―
Cryo-Cell International
―
DocGo
―
P3 Health Partners
―
Ownership Overview
44.85% Insiders
9.33% Mutual Funds
24.62% Other Institutional Investors
13.54% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---